Table 3.

Analysis of risks relative to the infusion of rituximab and ofatumumab

	Rituximab (N = 268)		Ofatumumab (N = 64)		Ofatumumab vs. rituximab
	Count	Rate	Count	Rate	Rate ratio
Infusion reactions	18	0.07 (0.04–0.11)	29	0.45 (0.31–0.65)	6.74 (3.74–12.15)
Early adverse events	18	0.07 (0.04–0.11)	6	0.09 (0.04–0.21)	1.39 (0.55–3.51)
Late adverse events	5	0.02 (0.01–0.04)	6	0.09 (0.04–0.21)	5.02 (1.53–16.46)
Total	41	0.15 (0.11–0.21)	41	0.64 (0.47–0.87)	4.18 (2.71–6.45)

Event counts, rates (per treatment; 95% confidence intervals) and rate ratio (95% confidence intervals) were calculated assuming a Poisson distribution